DexCom Inc (DXCM : NASDAQ)
Common Stock
$84.46
USD
-4.02 (-4.54%)
Last updated: 2026-11-05
Follow DXCM
DXCM
DexCom Inc
WealthAwesomePerformance
1 Day
+6.64%
1 Week
+12.54%
1 Month
+1.82%
YTD
+32.97%
Key Statistics
Market Cap
$31.50B
52W High
$92.59
52W Low
$54.20
P/E Ratio
33.25
50 Day MA
$85.49
200 Day MA
$74.79
Beta
1.44
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 11/5/2026 | $89.58 | $90.25 | $83.32 | $84.46 | $84.46 | 4,871,332 |
| 11/4/2026 | $85.06 | $88.96 | $84.75 | $88.48 | $88.48 | 4,821,412 |
| 11/3/2026 | $84.55 | $85.18 | $82.81 | $82.97 | $82.97 | 4,125,017 |
| 11/2/2026 | $82.94 | $85.19 | $82.52 | $84.76 | $84.76 | 4,058,776 |
| 10/30/2026 | $81.52 | $85.25 | $79.79 | $82.29 | $82.29 | 8,637,200 |
| 10/29/2026 | $79.08 | $80.01 | $78.59 | $79.93 | $79.93 | 5,909,294 |
| 10/28/2026 | $78.15 | $79.41 | $77.69 | $78.62 | $78.62 | 5,371,695 |
| 10/27/2026 | $78.58 | $79.86 | $78.05 | $78.56 | $78.56 | 5,159,356 |
| 10/26/2026 | $77.25 | $78.58 | $76.52 | $78.57 | $78.57 | 6,019,297 |
| 10/23/2026 | $78.68 | $79.51 | $77.82 | $77.94 | $77.94 | 5,218,200 |
Analyst Price Targets
Based on 29 analysts covering DXCM · as of Nov 3, 2026
Wall Street analysts forecast DXCM stock price to rise 16.2% over the next 12 months.
Consensus
Strong Buy4.66 / 5.00
Avg. Target
US$98.15
+16.2% Upside
Previously US$97.23 on Nov 2, 2026
Current Price
US$84.46
Last close
Analyst Breakdown (29 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on DXCM's historical volatility
30-Day Vol
41.5%
Annualized
90-Day Vol
41.0%
Annualized
Trend (90d)
-30.4%
Annualized drift
90d Mean
US$75.77
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$81.46 | US$70.58 – US$94.01 |
| 60 trading days | US$78.56 | US$64.15 – US$96.22 |
| 90 trading days | US$75.77 | US$59.11 – US$97.13 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About DexCom Inc
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Financials
- Revenue (TTM)
- $5.10B
- EBITDA
- $1.50B
- Profit Margin
- 19.42%
- ROE (TTM)
- 37.67%
- EPS (Diluted)
- 2.54
- Book Value
- 6.80
Classification
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Group
- Health Care Equipment & Services
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Common Questions About DXCM.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| INM | InMed Pharmaceuticals Inc | $17.50 | +941.67% |
| OMH | Ohmyhome Limited Ordinary Shares | $15.55 | +432.53% |
| CRIS | Curis Inc | $1.11 | +56.34% |
| PMAX | Powell Max Limited Class A Ordinary Shares | $1.04 | +54.07% |
| RFAIR | RF Acquisition Corp II Right | $0.24 | +50.00% |
| CRCT | Cricut Inc | $8.88 | +48.74% |
| LYEL | Lyell Immunopharma Inc | $15.43 | +43.27% |
| GENVR | Gen Digital Inc. Contingent Value Rights | $4.03 | +42.40% |
DXCM.US news timeline
12 articles covering DXCM.US, most recent first
LatestDexCom to Launch 15-Day G7 CGM System in Canada This November: What Investors Should Know
October 2026
- DexCom G7 15 Day System to Launch in Canada in November: What Investors Should Know
- Why Dexcom stock is rising today
- Why Dexcom stock is rising today
- Why Dexcom stock is tanking today
- Why Dexcom stock fell yesterday
- Why Dexcom stock is sliding today
- Why Dexcom stock is gaining today
- Why Dexcom stock is tanking today